|
Braz J Oral Sci, Vol. 9, No. 4, October-December, 2010, pp. 470-474 Risk factors for oral candidiasis in Brazilian HIV-infected adult patients Mariela Dutra Gontijo Moura1, Soraya de Mattos Camargo Grossman1, Linaena Méricy da Silva Fonseca2, Maria Letícia Ramos-Jorge3, Ricardo Alves Mesquita4 1MSc, Graduate students, Department of Oral Pathology, Dental School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil Received for publication: December 7, 2009 Accepted: August 27, 2010 Code Number: oc10057 Abstract Aim: The goals of this study were: 1) to estimate the prevalence of oral candidiasis
(OC) in a sample of Brazilian HIV-infected adult patients, and 2) to investigate
the risk factors for HIVassociated OC in this sample. Keywords: AIDS, candidiasis, HAART, HIV infection, prevalence ratio, risk factors. IntroductionOral candidiasis (OC) is the most frequent HIV infection-associated oral disease, and can also act as a marker for immunosuppression1-6. The prevalence and incidence of HIV infection in Brazil are 7.5% and 1.39%, respectively5. The literature supports the position that systemically applied antifungal drugs have the greatest efficacy for the treatment of OC. However, these therapies must be prescribed following a thorough assessment of the risk for developing drug-induced toxicities6. OC responds to antifungal therapy, but eradication is rarely achieved unless the underlying immune-compromised state is resolved2,7. Data about risk factors for HIV infection-associated oral lesions in the South American population are insufficient1,3,8. Some studies have identified potential risk factors for development of HIV-associated oral diseases3-4,7,9-11. Moura et al.4 demonstrated statistically significant associations between oral hairy leukoplakia (OHL) and HIV-1 viral load, OC, previous use of fluconazole and systemic acyclovir in Brazilian HIV-infected adult patients. Therefore, the goals of this study were: 1) to estimate the prevalence of OC in a sample of Brazilian HIV-infected adult patients, and 2) to investigate the risk factors for HIV-associated OC in this sample. Material and MethodsBetween 2002 and 2004, 112 HIV-infected adult volunteers were recruited from the Orestes Diniz Treatment Center of Parasitic and Infectious Diseases (CTR-DIP) (Belo Horizonte, MG, Brazil) to participate in this case-control study, approved by the UFMG’s Bioethics Research Committee (protocol number 339/03). All patients were first diagnosed with HIV-infection by enzyme-linked immunosorbant assay (ELISA) as the primary detection test, and the diagnoses were subsequently confirmed by the Western blot test. The diagnosis for HIV-infection had already been established during the period of the first exam for all patients. A single, validated examiner, trained in oral medicine, conducted the oral clinical exam in accordance with the World Health Organization standards12. OC diagnosis was based on the published standard presumptive clinical criteria of International Classification Systems13. Also, cytological features were considered in the diagnosis of OC: morphologic microscopic observation of fungal mycelial filaments from a non-cultured specimen scraped from the oral mucosa by Periodic Acid Schiff (PAS) staining. Patients with a confirmed diagnosis of OC were included in the case group; those without clinical features of OC were included in the control group. The following variables were obtained from the case and control groups: age, gender, race, route of transmission, CD4 T lymphocytes count, viral load, platelets count, salivary flow, xerostomia, OHL, previous use of fluconazole, previous use of systemic acyclovir, use of highly active anti-retroviral therapy (HAART), use of zidovudine (AZT), intravenous drug use, smoking, and alcohol consumption. The CD4 T lymphocyte count was divided into <200 cells/mm3 and >200 cells/mm3. The viral load was divided into <3,000 copies/µL and >3,000 copies/µL. Platelet count was divided into <150,000/mm3 and >150,000/mm3,4,14-16. The measurement of the salivary flow was performed through the collection of stimulated saliva, over the course of five minutes, in accordance to Tárzia17. The salivary flow was identified as normal (> 0.70mL/min), moderately low (0.50 to 0.70 mL/min), low (0.30 to 0.49 mL/min), or severely low (0 to 0.29 mL/min)17. Xerostomia was identified when the patient complained of dry mouth. The diagnosis of OHL was established according to clinical features and exfoliative cytology18-19. OHL was treated with topical applications of either podophyllin resin (25%) (prepared at UFMG’s pharmacy), or podophyllin resin (25%) together with acyclovir cream (5%) (EMS-Genéricos®, São Bernardo do Campo, SP, Brazil)20. Smoking individuals were identified as those who had smoked >100 cigarettes over their lifetime and smoked at the time of the study. Non-smoking individuals were identified as those who had not smoked >100 cigarettes in their lifetime16. Alcohol consumption was considered when the patient consumed alcohol on a daily basis. Statistical analysis of data was performed using the Statistical Package for Social Service (SPSS) software program (version 16.0, SPSS Inc., Chicago, IL, USA). Univariate analyses were performed on all variables of this study using the Fisher’s and Chi-squared tests (2-sided tests). Statistical significance was at a level of 0.05. The results of this analysis were expressed as an odds ratio (OR) with a 95% confidence interval (CI). Variables with p<0.25 were identified and included in the multivariate analyses. Multiple logistic regression techniques were then used to develop a model and identify the set of variables that may predict risk indicators in HIV-infected adult patients with OC. ResultsThe sample included 35 (31.3%) HIV-infected adult patients with OC and 77 (68.7%) patients who did not have OC. The majority of patients, 82 (73.2%), were men. Sixtyfive patients (58.0%) were Caucasian and 47 (42.0%) were Black. Age varied from 20 to 59 years (mean age of 39.5 years). Regarding the route of transmissions, the sample included 4 (3.6%) intravenous drug users, 13 (11.6%) not informed, 51 (45.5%) heterosexuals, 40 (35.7%) men who have sex with men (MSM) and 4 (3.6%) bisexuals. Of the 35 patients with OC, 20 (57.1%) were heterosexual, 8 (22.8%) were MSM, 2 (5.7%) were bisexual, 1 (2.8%) was intravenous drug user, and 4 (11.4%) did not inform. OC was erythematous in 19 cases (54.3%), pseudomembranous in 10 cases (28.6%), and both in 06 cases (17.1%). Angular cheilitis (9 cases) was also identified in our study, but all cases were in association with erythematous OC. Table 1 summarizes the proportional prevalence and univariate analyses. Statistically significant association was identified between the viral load of 3,000 copies/µL or greater (p=0.042; OR=2.3), the OHL (p<0.001; OR=10.2) and the previous use of fluconazole (p<0.001; OR=27.4) with OC. Platelets count (<150,000/mm3), HAART (patients that did not take), gender (men), reduction of salivary flow, previous use of systemic acyclovir, use of AZT (patients that did not take) and intravenous drug use (patients that did not use) were more frequently present in association with OC, though without a significant relationship (table 1). Table 2 demonstrates the logistic regression models. Multiple logistic regression tests confirmed the statistically significant association between the previous use of fluconazole and OHL with OC, regardless of the use of HAART. Adjusted results showed that HIV-infected patients with OHL, and those who had previously used fluconazole, were 3.6 times (95% CI=1.1-12.3) and 14.3 times (95% CI=3.8-53.6) more likely to present OC, respectively, regardless of the use of HAART. DiscussionIt has been suggested that OC represents a relevant marker of immune system status in HIV-infected patients, and is also a clinical predictor of AIDS progression3-4,7,11,14. the current study. In our study, this may be attributed to the In the present study, the prevalence of OC was 31.3%. Most fact that HAART is easily accessible in Brazil, especially in studies have reported prevalence rates of OC between 17.2% CTR-DIP, which contributes to the improvement of patient and 58.6%3,7,11,21. immunity, favoring an increase in the CD4 T lymphocyte It is intuitive to expect an increase of OC in patients count (>200 cells/mm3)4 . with low CD4 T lymphocyte count (<200 cells/mm3)3,7,9-Previous studies have reported a heterogeneous division 10,14,22-23. Campisi et al.24, Ghate et al.9 and Shiboski et al.25 of viral load, ranging from 3,000 to 30,000 copies/µL3,14,22did not find any relation between OC and low CD4 T 23,25. The high viral load presented a significant association lymphocyte count in HIV-infected adults, as is reflected in with OC, as reported in the findings of other studies3,14,23,25. Mercante et al.10 and Coogan et al.26 suggested that viral load may be a more important predictor for oropharyngeal candidiasis than CD4 T lymphocyte count. OC was more frequent in patients with platelet count <150,000, though without a significant association. Patton et al.27 observed that platelet count <150,000 may predispose HIV-infected patients to the development of oral manifestations, as verified in 15.5% of 516 patients. One possible explanation for our results is the fact that the number of individuals with platelet count <150,000 was small (1.7%). OC can be considered a measure of assessment of the need to begin antiretroviral medication11,7-8,11,14,25,28. In contrast, we did not find statistically significant association between HAART and OC. Tappuni and Fleming28 found no association between antiretroviral medication and the presence of OC. Thompson et al.1 confirmed that OC remains a significant infection in advanced AIDS, even with HAART. Gender, salivary flow, xerostomia, previous use of systemic acyclovir, use of AZT, intravenous drug use, smoking, and alcohol consumption do not represent risk indicators for OC7,14,24-26,29. Although it was not statistically significant, in the present study, OC was proportionally more frequent in men, in patients with a reduced salivary flow, with previous use of systemic acyclovir, who were not taking AZT and who did not use intravenously drug. Although our study was directed towards OC, the presence of OHL and OC was also verified, simultaneously, as being the two most common oral lesions in HIV-infected adults. The association between the presence of OC and OHL verified in this study has also been observed in many other studies in the US and Europe3,7,11,27,29. The previous use of fluconazole was a strong indicator of risk for OC. Schmidt-Westhausen et al.30 found different results, and they concluded that the presence of oral lesions associated with HIV-infection did not have a correlation with the use of fluconazole. It is possible that Candida resistance to fluconazole is responsible for our finding. The high incidence of mucosal and deep seated forms of candidiasis in HIV-infected patients has resulted in the use of fluconazole. Their widespread use has been followed by an increase in antifungal resistance and Candida resistance. Various factors may contribute to fluconazole resistance, such as the degree of immunosuppression of the patients, the chemotherapeutic use of drugs and the intrinsic resistance of Candida species2 . Fluconazole used for prolonged periods can select for less susceptible species Candida2. The resistance of Candida, isolated to currently available antifungal drugs, is a highly relevant factor because it presents important implications for morbidity and mortality1,6. Systemically applied antifungal drugs have the greatest efficacy for the treatment of oral candidiasis. However, these therapies must be prescribed following a thorough assessment of the risk for developing drug-induced toxicities, the likelihood of Candida species resistance, and the cost-effectiveness of medications. Fluconazole prophylaxis should be reserved for patients at high risk for recurrence of fungal infections, and not for routine prophylaxis6. Additionally, another explanation for the association of OC with previous use of fluconazole could be the fact that patients with HIV infection can have recurrent OC and that are treated with fluconazole1 . These results are important for the development of strategies to eliminate these indicators of risk and significantly reduce OC in Brazilian HIV-infected adult patients. AcknowledgementsThis study was supported by grants from the the National Council for Scientific and Technological Development (CNPq #301490/2007-4). Mesquita RA is research fellows of the CNPq. References
Copyright 2010 - Braz J Oral Sci The following images related to this document are available:Photo images[os10057t2.jpg] [os10057t1.jpg] |
|